mezigdomide + isatuximab + dexamethasone

This combination therapy consists of three agents: **mezigdomide**, **isatuximab**, and **dexamethasone**. - **Mezigdomide** is an oral cereblon E3 ligase modulator (CELMoD) that induces the degradation of transcription factors Ikaros and Aiolos, resulting in direct anti-myeloma activity and immunomodulatory effects[1]. - **Isatuximab** is a monoclonal antibody targeting CD38, leading to multiple antitumor mechanisms, including antibody-dependent cellular cytotoxicity, direct apoptosis, and immunomodulation[2]. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and cytotoxic effects, commonly used to enhance the activity of other anti-myeloma agents[2]. This triplet is under clinical investigation for **relapsed/refractory multiple myeloma**, especially in patients previously exposed or refractory to prior therapeutic classes. The combination is being investigated in ongoing studies (e.g., CC-92480-MM-002) to determine if it can confer synergistic anti-myeloma activity and improved outcomes compared to approved regimens[1].

Other names

mezigdomide + isatuximab + dexamethasoneMEZI + Isa + DEX